Therapeutics Pipeline

Our pipeline includes innovative, high-impact programs that reflect our commitment to translating cutting-edge science into meaningful therapeutic advances. In addition to those shown above, we have multiple assets spanning a range of modalities, including small molecule inhibitors (SMIs), bispecifics, molecular glues and antibody-radionuclide conjugates (ARCs). The selections below highlight programs that exemplify some of our most differentiated concepts, spanning both emerging innovations and efforts approaching key development milestones. 

Therapeutics Discovery's glutaminase (GLS1) inhibitor program continues to advance as a leading example of our commitment to developing innovative therapies for patients with high unmet need. IACS‑6274, discovered and developed within UT MD Anderson’s Therapeutics Discovery engine, has shown encouraging early antitumor activity, durable disease control in biomarker‑defined cancers and clear evidence of on‑target GLS1 inhibition in its ongoing Phase 1 trial. These results reflect years of integrated chemistry, biology and translational research across our matrixed platforms to identify patient populations most likely to benefit, including KEAP1/NFE2L2‑mutant NSCLC, ASNS‑low ovarian cancer and tumors resistant to immune checkpoint inhibitors. In parallel, IACS‑6274 is now being evaluated in combination with bevacizumab and paclitaxel, with enrollment that is progressing toward expansion. Together, these efforts highlight Therapeutics Discovery's goal to translate deep mechanistic insight into impactful therapies and to accelerate the development of first‑in‑class treatments for underserved patient groups.

Therapeutics Discovery is advancing a new class of TCR mimetic (TCRm) bispecific antibodies designed to activate highly targeted immune responses against cancer. These therapies mimic the T cell receptor, enabling recognition of intracellular tumor antigens and redirecting T cells to cancer cells via CD3 engagement. OBT221, our leading CCNB1/HLAA2directed TCRm bispecific, reflects the promise of this approach. It shows strong, selective binding to CCNB1 peptide presented to HLA-A*02, demonstrates directed TCRm bispecific, reflects the promise of this approach. It shows strong, selective binding to CCNB1 peptide presented to HLA-A*02, demonstrates solid stability and developability, and delivers clear anti-tumor activity in preclinical models. Importantly, it has been well tolerated in early safety studies using humanized mouse models. With these encouraging results, OBT221 is moving toward CMC, and IND221 is moving toward CMC and IND enabling studies as part of Therapeutics Discovery's broader effort to unlock new classes of targets and deliver next-enabling studies as part of Therapeutics Discovery’s broader effort to unlock new classes of targets and deliver next-generation immunotherapies for solid tumors.

Therapeutics Discovery is advancing a focused discovery engine for Cancer Selective Proximity Targeting (CSPT) agents, an emerging class of heterobifunctional molecules designed to selectively eliminate cancer cells while sparing healthy tissue. CSPTs act by bringing together a cancer-associated target specific protein (TSP) and a pan essential effector protein (EP), disrupting EP function only in TSP expressing cells and enabling highly selective tumor cell killing, even when the TSP is not a disease driver. To accelerate program maturation, Therapeutics Discovery established dedicated assays and screening platforms for early hit identification and will be nominating programs once hits show clear differential sensitivity between targeted and control models. A structured funnel has been set in place to guide rapid hit identification through direct-to-biology approaches and follow up SAR through integrated biochemical and cell-based assays. Therapeutics Discovery expertise in CSPT is driving progress toward demonstrating in vivo activity and advancing an orally bioavailable lead. Our disciplined, milestone driven framework is enabling rapid identification and advancement of first in class and best-in-class CSPT therapeutics into translational development, thereby supporting our plan to nominate the first CSPT candidate in 2026 and to evaluate three to four new concepts each year.

Therapeutics Discovery spearheaded the discovery and translational development of ART0380 (alnodesertib), a first‑in‑class ATR inhibitor now advancing in the clinic through our partnership with Artios Pharma. Through an intensive medicinal chemistry effort that produced more than 700 compounds, Therapeutics Discovery identified ART0380 for its superior pharmacologic profile and then built the scientific framework that defined its precision‑oncology strategy, demonstrating potent synthetic lethality in ATM‑deficient tumors and establishing biomarker‑driven patient selection. These foundational insights directly enabled the strong clinical performance now emerging from Artios’s STELLA Phase 1/2a trial, where alnodesertib combined with low‑dose irinotecan has shown compelling and durable responses across multiple hard‑to‑treat solid tumors, including a 50% confirmed response rate in ATM‑negative cancers. The FDA’s Fast Track designation for alnodesertib in third‑line ATM‑negative metastatic colorectal cancer underscores the program’s transformative potential and accelerates its path toward pivotal studies. As expansion cohorts open in earlier‑line pancreatic and colorectal cancers, Therapeutics Discovery’s discovery leadership and translational innovation continue to drive this therapy from concept to clinical impact, reinforcing UT MD Anderson’s commitment to advancing breakthrough treatments for patients with urgent unmet needs.